Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs)

bench to bedside

Authors

  • Ali Hassanzadeh Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran https://orcid.org/0000-0002-0734-3888
  • Navid Shomali Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran https://orcid.org/0000-0003-4679-9658
  • Amin Kamrani Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran https://orcid.org/0000-0001-9845-9140
  • Mohammad Sadegh Soltani-Zangbar Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran https://orcid.org/0000-0003-3960-5712
  • Hadi Nasiri Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran https://orcid.org/0000-0002-9090-0752
  • Morteza Akbari Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. E-mail: mortezaakbari25@yahoo.com https://orcid.org/0000-0001-7333-1300

DOI:

https://doi.org/10.17179/excli2024-7076

Keywords:

cancer, cyclin-dependent kinases (CDKs), CDK inhibitors (CDKIs), treatment

Abstract

A major characteristic of cancer is dysregulated cell division, which results in aberrant growth of cells. Consequently, medicinal targets that prevent cell division would be useful in the fight against cancer. The primary regulator of proliferation is a complex consisting of cyclin and cyclin-dependent kinases (CDKs). The FDA has granted approval for CDK inhibitors (CDKIs) to treat metastatic hormone receptor-positive breast cancer. Specifically, CDK4/6 CDKIs block the enzyme activity of CDK4 and CDK6. Unfortunately, the majority of first-generation CDK inhibitors, also known as pan-CDK inhibitors because they target multiple CDKs, have not been authorized for clinical use owing to their serious side effects and lack of selection. In contrast to this, significant advancements have been created to permit the use of pan-CDK inhibitors in therapeutic settings. Notably, the toxicity and negative consequences of pan-CDK inhibitors have been lessened in recent years thanks to the emergence of combination therapy tactics. Therefore, pan-CDK inhibitors have renewed promise for clinical use when used in a combination regimen. The members of the CDK family have been reviewed and their primary roles in cell cycle regulation were covered in this review. Next, we provided an overview of the state of studies on CDK inhibitors.

Downloads

Published

2024-06-04

How to Cite

Hassanzadeh, A., Shomali, N., Kamrani, A., Soltani-Zangbar, M. S., Nasiri, H., & Akbari, M. (2024). Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside. EXCLI Journal, 23, 862–882. https://doi.org/10.17179/excli2024-7076

Issue

Section

Review articles

Categories

Most read articles by the same author(s)